Publications

5891 Results

Prognostic and molecular multi-platform analysis of CALGB 40603 (Alliance) and public triple-negative breast cancer datasets

Authors
Felsheim BM;Fernandez-Martinez A;Fan C;Pfefferle AD;Hayward MC;Hoadley KA;Rashid NU;Tolaney SM;Somlo G;Carey LA;Sikov WM;Perou CM
Journal / Conference
NPJ Breast Cancer. 2025 Mar 8;11(1):24. doi: 10.1038/s41523-025-00740-z
Year
2025
Research Committee(s)
Breast
PMID
PMID40057511
PMC
PMC11890565
Study Number(s)
CTSU/C40603

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC)

Authors
Fernandez-Martinez A;Tanioka M;Ahn SG;Zagami P;Pascual T;Rediti M;Tang G;Hoadley KA;Venet D;Rashid NU;Spears PA;Di Cosimo S;de Azambuja E;Choudhury A;Rastogi P;Islam MN;Cortes J;Llombart-Cussac A;Swain SM;Sotiriou C;Prat A;Perou CM;Carey LA
Journal / Conference
Annals of Oncology 2025 Apr;36(4):403-413. doi: 10.1016/j.annonc.2024.12.010. Epub 2024 Dec 18.NIHMS2052322
Year
2025
Research Committee(s)
Breast
PMID
PMID39706338
PMC
PMC11949722

Patient rights in precision oncology: right treatment, right time, right dose, right order, right place

Authors
Fountzilas E;Tsimberidou AM;Kurzrock R
Journal / Conference
Genome Med. 2025 May 12;17(1):53. doi: 10.1186/s13073-025-01468-y
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID40355948
PMC
PMC12070537

Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials

Authors
Germani MM;Borelli B;Hashimoto T;Nakamura Y;Oldani S;Battaglin F;Bergamo F;Salvatore L;Stahler A;Antoniotti C;Shitara K;Venook A;Oki E;Muro K;Ugolini C;Soeda J;Lonardi S;Pietrantonio F;Lenz HJ;Modest DP;Yoshino T;Cremolini C
Journal / Conference
J Clin Oncol. 2025 Oct 10;43(29):3184-3197. doi: 10.1200/JCO-25-01003. Epub 2025 Sep 4.
Year
2025
Research Committee(s)
Gastrointestinal
PMID
PMID40906970
PMC
PMC12509457
Study Number(s)
CTSU/C80405

Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

Authors
Gouda MA;Wei Z;Rodon J;Davies MA;Janku F;Gray RJ;Wang V;McShane LM;Rubinstein LV;Patton DR;Williams PM;Hamilton SR;Liu R;Bota DA;Swiecicki PL;Buchschacher GL;Tricoli JV;Conley BA;Arteaga CL;Harris LN;O’Dwyer PJ;Chen AP;Flaherty KT
Journal / Conference
JCO Precis Oncol. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6.NIHMS2058197
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID39913886
PMC
PMC12002398
Study Number(s)
CTSU/EAY131

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Authors
Gouda MA;Gouda MA;Janku F;Yuan Y;Drusbosky LM;Chen AP;Zheng X;Patel K;Hamilton SR;Routbort M;Tricoli JV;Williams PM;Iafrate AJ;Sklar J;Coffey B;Little RF;Arteaga CL;O’Dwyer PJ;Flaherty KT;Harris LN;Meric-Bernstam F
Journal / Conference
Clin Cancer Res. 2025 Oct 15;31(20):4299-4310. doi: 10.1158/1078-0432.CCR-24-3531.NIHMS2084882
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID40388547
PMC
PMC12383705
Study Number(s)
CTSU/EAY131

Design considerations and challenges in the CHinA National CancEr Screening (CHANCES) trial and Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Authors
Hu P;Steingrimsson JA;Cole E;Cormack J;Dunn BK;Gatsonis C;Lee C;Li N;Pisano ED;He J;Kramer BS
Journal / Conference
J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):42-48. doi: 10.1093/jncimonographs/lgae049
Year
2025
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID39989037
PMC
PMC11848039
Study Number(s)
CTSU/EA1151

Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features

Authors
Iacobucci I;Zeng AGX;Gao Q;Garcia-Prat L;Baviskar P;Shah S;Murison A;Voisin V;Chan-Seng-Yue M;Cheng C;Qu C;Bailey C;Lear M;Witkowski MT;Zhou X;Zaldivar Peraza A;Gangwani K;Advani AS;Luger SM;Litzow MR;Rowe JM;Paietta EM;Stock W;Dick JE;Mullighan CG
Journal / Conference
Nature Cancer. 2025 Jul;6(7):1242-1262. doi: 10.1038/s43018-025-00987-2. Epub 2025 Jun 27.NIHMS2100933
Year
2025
Research Committee(s)
Leukemia
PMID
PMID40579588
PMC
PMC12377259

The fundamentals of multiplicity adjustment in biostatistics

Authors
Izmirlian G;Sirota LA;Berger VW;Kipnis V
Journal / Conference
J Natl Cancer Inst Monogr. 2025 Mar 1;2025(68):10-13. doi: 10.1093/jncimonographs/lgae050
Year
2025
Research Committee(s)
Cancer Care Delivery
PMID
PMID39989036
PMC
PMC11848033

Ag(e)nostic precision oncology therapy approvals across the years

Authors
Kudek MR;Adashek JJ;Kurzrock R
Journal / Conference
Trends Cancer. 2025 Aug;11(8):726-735. doi: 10.1016/j.trecan.2025.04.015. Epub 2025 Jun 5.NIHMS2077750
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID40480903
PMC
PMC12350067